Kwonjune Justin Seung, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Tuberculosis, Multidrug-Resistant | 47 | 2024 | 934 | 7.160 |
Why?
|
Antitubercular Agents | 45 | 2024 | 1374 | 5.540 |
Why?
|
Nitroimidazoles | 8 | 2024 | 117 | 2.120 |
Why?
|
Tuberculosis, Pulmonary | 13 | 2024 | 830 | 1.690 |
Why?
|
Oxazoles | 8 | 2024 | 199 | 1.320 |
Why?
|
Rifampin | 11 | 2024 | 338 | 1.010 |
Why?
|
Lesotho | 11 | 2024 | 73 | 0.880 |
Why?
|
Clofazimine | 6 | 2024 | 41 | 0.830 |
Why?
|
Extensively Drug-Resistant Tuberculosis | 6 | 2023 | 85 | 0.610 |
Why?
|
Tuberculosis | 5 | 2020 | 2016 | 0.560 |
Why?
|
Sputum | 7 | 2024 | 505 | 0.560 |
Why?
|
Mycobacterium tuberculosis | 9 | 2024 | 1912 | 0.540 |
Why?
|
Financing, Organized | 1 | 2018 | 204 | 0.530 |
Why?
|
Financial Management | 1 | 2018 | 160 | 0.530 |
Why?
|
Pharmaceutical Preparations | 2 | 2021 | 1086 | 0.490 |
Why?
|
Isoniazid | 4 | 2015 | 283 | 0.470 |
Why?
|
Fluoroquinolones | 6 | 2023 | 307 | 0.460 |
Why?
|
HIV Infections | 10 | 2024 | 17347 | 0.450 |
Why?
|
Capacity Building | 1 | 2016 | 259 | 0.450 |
Why?
|
Mycobacterium | 1 | 2013 | 251 | 0.390 |
Why?
|
International Cooperation | 1 | 2018 | 1423 | 0.380 |
Why?
|
Comprehensive Health Care | 1 | 2012 | 123 | 0.380 |
Why?
|
Bacterial Shedding | 1 | 2010 | 10 | 0.360 |
Why?
|
Drug Therapy, Combination | 10 | 2024 | 6304 | 0.360 |
Why?
|
Antibiotics, Antitubercular | 3 | 2018 | 99 | 0.350 |
Why?
|
Hepatitis C | 1 | 2020 | 1579 | 0.340 |
Why?
|
Pyrazinamide | 4 | 2024 | 60 | 0.320 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2012 | 662 | 0.320 |
Why?
|
Thyrotropin | 1 | 2012 | 833 | 0.310 |
Why?
|
Malaria | 1 | 2018 | 1225 | 0.300 |
Why?
|
Treatment Outcome | 23 | 2024 | 64681 | 0.290 |
Why?
|
Hypothyroidism | 1 | 2012 | 668 | 0.280 |
Why?
|
Salvage Therapy | 1 | 2013 | 1264 | 0.270 |
Why?
|
Patient Simulation | 1 | 2008 | 297 | 0.270 |
Why?
|
Respiratory Tract Diseases | 1 | 2012 | 748 | 0.260 |
Why?
|
Democratic People's Republic of Korea | 2 | 2016 | 12 | 0.250 |
Why?
|
Drug Resistance, Bacterial | 3 | 2013 | 1048 | 0.240 |
Why?
|
Respiratory Tract Infections | 1 | 2012 | 1009 | 0.220 |
Why?
|
Ethambutol | 2 | 2018 | 59 | 0.210 |
Why?
|
Kanamycin | 3 | 2018 | 63 | 0.210 |
Why?
|
Directly Observed Therapy | 4 | 2008 | 139 | 0.210 |
Why?
|
Health Resources | 1 | 2008 | 934 | 0.200 |
Why?
|
Drug Repositioning | 2 | 2024 | 233 | 0.200 |
Why?
|
Humans | 63 | 2024 | 761208 | 0.190 |
Why?
|
Drug Administration Schedule | 3 | 2019 | 4851 | 0.180 |
Why?
|
Anti-HIV Agents | 2 | 2013 | 4526 | 0.170 |
Why?
|
Capreomycin | 2 | 2018 | 14 | 0.150 |
Why?
|
Microbial Sensitivity Tests | 4 | 2014 | 1936 | 0.150 |
Why?
|
Administration, Oral | 3 | 2024 | 4015 | 0.140 |
Why?
|
Multicenter Studies as Topic | 2 | 2019 | 1702 | 0.140 |
Why?
|
Prevalence | 6 | 2020 | 15721 | 0.140 |
Why?
|
Curriculum | 1 | 2008 | 3741 | 0.120 |
Why?
|
Health Personnel | 1 | 2008 | 3337 | 0.120 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 2270 | 0.120 |
Why?
|
World Health Organization | 4 | 2023 | 1321 | 0.120 |
Why?
|
Korea | 2 | 2004 | 98 | 0.110 |
Why?
|
Cycloserine | 2 | 2024 | 118 | 0.110 |
Why?
|
Amoxicillin-Potassium Clavulanate Combination | 1 | 2013 | 33 | 0.110 |
Why?
|
Adult | 24 | 2024 | 221119 | 0.110 |
Why?
|
Clarithromycin | 1 | 2013 | 86 | 0.110 |
Why?
|
Clinical Protocols | 3 | 2024 | 1436 | 0.110 |
Why?
|
Prospective Studies | 8 | 2024 | 54435 | 0.110 |
Why?
|
Community Health Services | 2 | 2015 | 654 | 0.100 |
Why?
|
Primary Health Care | 3 | 2014 | 4678 | 0.100 |
Why?
|
HIV Seroprevalence | 1 | 2012 | 89 | 0.100 |
Why?
|
Maternal Welfare | 1 | 2012 | 112 | 0.100 |
Why?
|
Electrolytes | 2 | 2022 | 274 | 0.100 |
Why?
|
Streptomycin | 2 | 2018 | 69 | 0.100 |
Why?
|
Female | 26 | 2024 | 392544 | 0.090 |
Why?
|
Drug Resistance, Multiple, Bacterial | 3 | 2004 | 585 | 0.090 |
Why?
|
Retrospective Studies | 12 | 2013 | 80674 | 0.090 |
Why?
|
National Health Programs | 2 | 2004 | 440 | 0.090 |
Why?
|
Male | 23 | 2024 | 360693 | 0.090 |
Why?
|
Africa, Southern | 1 | 2009 | 60 | 0.080 |
Why?
|
Drug Design | 1 | 2015 | 1045 | 0.080 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2023 | 10218 | 0.080 |
Why?
|
Public Health | 1 | 2023 | 2672 | 0.080 |
Why?
|
Pneumonectomy | 1 | 2016 | 1118 | 0.080 |
Why?
|
Anti-Retroviral Agents | 2 | 2008 | 1784 | 0.080 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2015 | 2150 | 0.080 |
Why?
|
Drug Resistance, Viral | 1 | 2013 | 862 | 0.070 |
Why?
|
Cohort Studies | 7 | 2022 | 41496 | 0.070 |
Why?
|
Bacterial Proteins | 1 | 2021 | 3836 | 0.070 |
Why?
|
Middle Aged | 12 | 2024 | 220853 | 0.070 |
Why?
|
Maternal Health Services | 1 | 2012 | 460 | 0.070 |
Why?
|
Adolescent | 9 | 2021 | 88298 | 0.060 |
Why?
|
Drug Monitoring | 1 | 2012 | 961 | 0.060 |
Why?
|
Health Services Needs and Demand | 1 | 2013 | 1401 | 0.060 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2014 | 940 | 0.060 |
Why?
|
Young Adult | 7 | 2024 | 59221 | 0.060 |
Why?
|
Practice Guidelines as Topic | 2 | 2021 | 7400 | 0.060 |
Why?
|
Radiography, Thoracic | 1 | 2012 | 1302 | 0.060 |
Why?
|
Siberia | 1 | 2004 | 30 | 0.060 |
Why?
|
Kazakhstan | 1 | 2024 | 19 | 0.060 |
Why?
|
Prothionamide | 1 | 2004 | 3 | 0.060 |
Why?
|
Aminosalicylic Acid | 1 | 2004 | 20 | 0.060 |
Why?
|
Treatment Failure | 3 | 2018 | 2643 | 0.060 |
Why?
|
Ofloxacin | 1 | 2004 | 66 | 0.060 |
Why?
|
Cost of Illness | 1 | 2014 | 1936 | 0.060 |
Why?
|
Self Administration | 1 | 2004 | 387 | 0.050 |
Why?
|
Child | 5 | 2021 | 80152 | 0.050 |
Why?
|
Algorithms | 1 | 2023 | 14025 | 0.050 |
Why?
|
Drug Resistance, Multiple | 1 | 2003 | 255 | 0.050 |
Why?
|
Public Sector | 1 | 2003 | 264 | 0.050 |
Why?
|
Administrative Personnel | 1 | 2023 | 183 | 0.050 |
Why?
|
Pregnancy | 4 | 2024 | 29893 | 0.050 |
Why?
|
Delivery of Health Care | 3 | 2014 | 5333 | 0.050 |
Why?
|
Developing Countries | 1 | 2014 | 2863 | 0.050 |
Why?
|
Acute Disease | 1 | 2012 | 7226 | 0.050 |
Why?
|
Patents as Topic | 1 | 2021 | 111 | 0.040 |
Why?
|
Private Sector | 1 | 2003 | 394 | 0.040 |
Why?
|
Live Birth | 1 | 2024 | 511 | 0.040 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2008 | 2196 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2023 | 858 | 0.040 |
Why?
|
Child, Preschool | 3 | 2012 | 42224 | 0.040 |
Why?
|
Amikacin | 1 | 2018 | 47 | 0.040 |
Why?
|
Peru | 3 | 2008 | 888 | 0.040 |
Why?
|
Off-Label Use | 1 | 2020 | 185 | 0.040 |
Why?
|
Patient Education as Topic | 1 | 2008 | 2317 | 0.040 |
Why?
|
Comorbidity | 1 | 2012 | 10516 | 0.040 |
Why?
|
Carbapenems | 1 | 2018 | 123 | 0.040 |
Why?
|
Aged, 80 and over | 3 | 2021 | 58952 | 0.030 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2009 | 4372 | 0.030 |
Why?
|
Chronic Disease | 1 | 2012 | 9319 | 0.030 |
Why?
|
HIV | 1 | 2024 | 1581 | 0.030 |
Why?
|
Health Literacy | 1 | 2021 | 444 | 0.030 |
Why?
|
Review Literature as Topic | 1 | 2018 | 348 | 0.030 |
Why?
|
Bone Morphogenetic Proteins | 2 | 1997 | 840 | 0.030 |
Why?
|
Forecasting | 1 | 2003 | 2928 | 0.030 |
Why?
|
Retreatment | 2 | 2006 | 598 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2016 | 628 | 0.030 |
Why?
|
Disease Outbreaks | 1 | 2023 | 1747 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2021 | 2329 | 0.030 |
Why?
|
Recurrence | 2 | 2018 | 8457 | 0.030 |
Why?
|
Nurse Midwives | 1 | 2012 | 23 | 0.030 |
Why?
|
Odds Ratio | 2 | 2014 | 9652 | 0.020 |
Why?
|
Health Policy | 1 | 2003 | 2679 | 0.020 |
Why?
|
Midwifery | 1 | 2012 | 124 | 0.020 |
Why?
|
Combined Modality Therapy | 2 | 2016 | 8519 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 2012 | 26071 | 0.020 |
Why?
|
Research Design | 1 | 2006 | 6180 | 0.020 |
Why?
|
Muscles | 1 | 1994 | 1568 | 0.020 |
Why?
|
Maternal Mortality | 1 | 2012 | 301 | 0.020 |
Why?
|
Aged | 3 | 2021 | 169288 | 0.020 |
Why?
|
Point Mutation | 1 | 1994 | 1593 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 1997 | 1852 | 0.020 |
Why?
|
HIV Seronegativity | 1 | 2008 | 211 | 0.020 |
Why?
|
Abnormalities, Multiple | 1 | 1994 | 1423 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2012 | 2928 | 0.020 |
Why?
|
Program Development | 1 | 2012 | 1294 | 0.020 |
Why?
|
Body Mass Index | 1 | 2024 | 12952 | 0.020 |
Why?
|
Obstetrics | 1 | 2012 | 668 | 0.020 |
Why?
|
Delivery, Obstetric | 1 | 2012 | 941 | 0.020 |
Why?
|
Prenatal Care | 1 | 2012 | 1141 | 0.010 |
Why?
|
Mice, Inbred C3H | 2 | 1997 | 914 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2013 | 6223 | 0.010 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 2005 | 765 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2016 | 10756 | 0.010 |
Why?
|
Bone and Bones | 1 | 1994 | 2568 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2024 | 26199 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2008 | 1838 | 0.010 |
Why?
|
Disease Management | 1 | 2014 | 2507 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8663 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2024 | 39126 | 0.010 |
Why?
|
Drug Tolerance | 1 | 2003 | 367 | 0.010 |
Why?
|
Pregnancy Outcome | 1 | 2012 | 2923 | 0.010 |
Why?
|
Risk Factors | 3 | 2014 | 74239 | 0.010 |
Why?
|
Proteins | 1 | 1994 | 5993 | 0.010 |
Why?
|
Social Support | 1 | 2008 | 2175 | 0.010 |
Why?
|
Ambulatory Care | 1 | 2008 | 2770 | 0.010 |
Why?
|
Polymerase Chain Reaction | 2 | 1997 | 6067 | 0.010 |
Why?
|
Base Sequence | 2 | 1997 | 12404 | 0.010 |
Why?
|
Oligonucleotide Probes | 1 | 1994 | 416 | 0.010 |
Why?
|
Amino Acid Sequence | 2 | 1997 | 13402 | 0.010 |
Why?
|
DNA, Complementary | 1 | 1997 | 1989 | 0.010 |
Why?
|
Molecular Sequence Data | 2 | 1997 | 17598 | 0.010 |
Why?
|
Codon | 1 | 1994 | 597 | 0.010 |
Why?
|
Mutagenesis | 1 | 1997 | 1226 | 0.010 |
Why?
|
Growth Substances | 1 | 1994 | 759 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2007 | 12976 | 0.010 |
Why?
|
Ureter | 1 | 1994 | 368 | 0.010 |
Why?
|
Mice, Mutant Strains | 1 | 1994 | 1751 | 0.010 |
Why?
|
Time Factors | 1 | 2013 | 39957 | 0.010 |
Why?
|
DNA Primers | 1 | 1994 | 2814 | 0.010 |
Why?
|
Urinary Bladder | 1 | 1994 | 1152 | 0.000 |
Why?
|
Incidence | 1 | 2006 | 21365 | 0.000 |
Why?
|
Protein Biosynthesis | 1 | 1994 | 2091 | 0.000 |
Why?
|
Reference Values | 1 | 1994 | 4921 | 0.000 |
Why?
|
Gestational Age | 1 | 1994 | 3580 | 0.000 |
Why?
|
Intestines | 1 | 1994 | 1908 | 0.000 |
Why?
|
Gene Expression | 1 | 1994 | 7571 | 0.000 |
Why?
|
Liver | 1 | 1994 | 7514 | 0.000 |
Why?
|
Mice | 2 | 1997 | 81326 | 0.000 |
Why?
|
Lung | 1 | 1994 | 9979 | 0.000 |
Why?
|
Animals | 2 | 1997 | 168079 | 0.000 |
Why?
|